img

Global Viral Vector Vaccines Market Insights, Forecast to 2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Viral Vector Vaccines Market Insights, Forecast to 2034

Viral vector vaccines combine many of the positive qualities of DNA vaccines with those of live attenuated vaccines.
The global Viral Vector Vaccines market is projected to grow from US$ million in 2024 to US$ million by 2034, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Viral Vector Vaccines is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The China market for Viral Vector Vaccines is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The Europe market for Viral Vector Vaccines is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The global key manufacturers of Viral Vector Vaccines include Advanced Bioscience Laboratories, Boehringer Ingelheim, Brammer Bio, Creative Biogene, GE Healthcare, Pfizer and Sanofi, etc. In 2022, the global top five players had a share approximately % in terms of revenue.

Report Includes


This report presents an overview of global market for Viral Vector Vaccines, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2018 - 2022, estimates for 2024, and projections of CAGR through 2034.
This report researches the key producers of Viral Vector Vaccines, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Viral Vector Vaccines, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Viral Vector Vaccines sales, revenue, market share and industry ranking of main manufacturers, data from 2018 to 2024. Identification of the major stakeholders in the global Viral Vector Vaccines market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, sales, revenue, and price, from 2018 to 2034. Evaluation and forecast the market size for Viral Vector Vaccines sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Advanced Bioscience Laboratories, Boehringer Ingelheim, Brammer Bio, Creative Biogene, GE Healthcare, Pfizer and Sanofi, etc.



By Company


Advanced Bioscience Laboratories
Boehringer Ingelheim
Brammer Bio
Creative Biogene
GE Healthcare
Pfizer
Sanofi
Segment by Type
Adenovirus
Fowlpox Virus
Attenuated Yellow Fever
Vaccinia Virus Vectors
Others

Segment by Application


Hospitals
Clinics
Others

Segment by Region


US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (by type and application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Sales (consumption), revenue of Viral Vector Vaccines in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3Detailed analysis of Viral Vector Vaccines manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6US & Canada (US & Canada) by type, by application and by country, sales and revenue for each segment.
Chapter 7Europe by type, by application and by country, sales and revenue for each segment.
Chapter 8China by type, by application sales and revenue for each segment.
Chapter 9Asia (excluding China) by type, by application and by region, sales and revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by type, by application and by country, sales and revenue for each segment.
Chapter 11Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Viral Vector Vaccines sales, revenue, price, gross margin, and recent development, etc.
Chapter 12Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14The main points and conclusions of the report.

Table of Content

1 Study Coverage
1.1 Viral Vector Vaccines Product Introduction
1.2 Market by Type
1.2.1 Global Viral Vector Vaccines Market Size Growth Rate by Type, 2018 VS 2022 VS 2034
1.2.2 Adenovirus
1.2.3 Fowlpox Virus
1.2.4 Attenuated Yellow Fever
1.2.5 Vaccinia Virus Vectors
1.2.6 Others
1.3 Market by Application
1.3.1 Global Viral Vector Vaccines Market Size Growth Rate by Application, 2018 VS 2022 VS 2034
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Viral Vector Vaccines Sales Estimates and Forecasts 2018-2034
2.2 Global Viral Vector Vaccines Revenue by Region
2.2.1 Global Viral Vector Vaccines Revenue by Region: 2018 VS 2022 VS 2034
2.2.2 Global Viral Vector Vaccines Revenue by Region (2018-2024)
2.2.3 Global Viral Vector Vaccines Revenue by Region (2024-2034)
2.2.4 Global Viral Vector Vaccines Revenue Market Share by Region (2018-2034)
2.3 Global Viral Vector Vaccines Sales Estimates and Forecasts 2018-2034
2.4 Global Viral Vector Vaccines Sales by Region
2.4.1 Global Viral Vector Vaccines Sales by Region: 2018 VS 2022 VS 2034
2.4.2 Global Viral Vector Vaccines Sales by Region (2018-2024)
2.4.3 Global Viral Vector Vaccines Sales by Region (2024-2034)
2.4.4 Global Viral Vector Vaccines Sales Market Share by Region (2018-2034)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Viral Vector Vaccines Sales by Manufacturers
3.1.1 Global Viral Vector Vaccines Sales by Manufacturers (2018-2024)
3.1.2 Global Viral Vector Vaccines Sales Market Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Viral Vector Vaccines in 2022
3.2 Global Viral Vector Vaccines Revenue by Manufacturers
3.2.1 Global Viral Vector Vaccines Revenue by Manufacturers (2018-2024)
3.2.2 Global Viral Vector Vaccines Revenue Market Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Viral Vector Vaccines Revenue in 2022
3.3 Global Key Players of Viral Vector Vaccines, Industry Ranking, 2021 VS 2022 VS 2024
3.4 Global Viral Vector Vaccines Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Viral Vector Vaccines Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Viral Vector Vaccines, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Viral Vector Vaccines, Product Offered and Application
3.8 Global Key Manufacturers of Viral Vector Vaccines, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Viral Vector Vaccines Sales by Type
4.1.1 Global Viral Vector Vaccines Historical Sales by Type (2018-2024)
4.1.2 Global Viral Vector Vaccines Forecasted Sales by Type (2024-2034)
4.1.3 Global Viral Vector Vaccines Sales Market Share by Type (2018-2034)
4.2 Global Viral Vector Vaccines Revenue by Type
4.2.1 Global Viral Vector Vaccines Historical Revenue by Type (2018-2024)
4.2.2 Global Viral Vector Vaccines Forecasted Revenue by Type (2024-2034)
4.2.3 Global Viral Vector Vaccines Revenue Market Share by Type (2018-2034)
4.3 Global Viral Vector Vaccines Price by Type
4.3.1 Global Viral Vector Vaccines Price by Type (2018-2024)
4.3.2 Global Viral Vector Vaccines Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Viral Vector Vaccines Sales by Application
5.1.1 Global Viral Vector Vaccines Historical Sales by Application (2018-2024)
5.1.2 Global Viral Vector Vaccines Forecasted Sales by Application (2024-2034)
5.1.3 Global Viral Vector Vaccines Sales Market Share by Application (2018-2034)
5.2 Global Viral Vector Vaccines Revenue by Application
5.2.1 Global Viral Vector Vaccines Historical Revenue by Application (2018-2024)
5.2.2 Global Viral Vector Vaccines Forecasted Revenue by Application (2024-2034)
5.2.3 Global Viral Vector Vaccines Revenue Market Share by Application (2018-2034)
5.3 Global Viral Vector Vaccines Price by Application
5.3.1 Global Viral Vector Vaccines Price by Application (2018-2024)
5.3.2 Global Viral Vector Vaccines Price Forecast by Application (2024-2034)
6 US & Canada
6.1 US & Canada Viral Vector Vaccines Market Size by Type
6.1.1 US & Canada Viral Vector Vaccines Sales by Type (2018-2034)
6.1.2 US & Canada Viral Vector Vaccines Revenue by Type (2018-2034)
6.2 US & Canada Viral Vector Vaccines Market Size by Application
6.2.1 US & Canada Viral Vector Vaccines Sales by Application (2018-2034)
6.2.2 US & Canada Viral Vector Vaccines Revenue by Application (2018-2034)
6.3 US & Canada Viral Vector Vaccines Market Size by Country
6.3.1 US & Canada Viral Vector Vaccines Revenue by Country: 2018 VS 2022 VS 2034
6.3.2 US & Canada Viral Vector Vaccines Sales by Country (2018-2034)
6.3.3 US & Canada Viral Vector Vaccines Revenue by Country (2018-2034)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Viral Vector Vaccines Market Size by Type
7.1.1 Europe Viral Vector Vaccines Sales by Type (2018-2034)
7.1.2 Europe Viral Vector Vaccines Revenue by Type (2018-2034)
7.2 Europe Viral Vector Vaccines Market Size by Application
7.2.1 Europe Viral Vector Vaccines Sales by Application (2018-2034)
7.2.2 Europe Viral Vector Vaccines Revenue by Application (2018-2034)
7.3 Europe Viral Vector Vaccines Market Size by Country
7.3.1 Europe Viral Vector Vaccines Revenue by Country: 2018 VS 2022 VS 2034
7.3.2 Europe Viral Vector Vaccines Sales by Country (2018-2034)
7.3.3 Europe Viral Vector Vaccines Revenue by Country (2018-2034)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Viral Vector Vaccines Market Size
8.1.1 China Viral Vector Vaccines Sales (2018-2034)
8.1.2 China Viral Vector Vaccines Revenue (2018-2034)
8.2 China Viral Vector Vaccines Market Size by Application
8.2.1 China Viral Vector Vaccines Sales by Application (2018-2034)
8.2.2 China Viral Vector Vaccines Revenue by Application (2018-2034)
9 Asia (excluding China)
9.1 Asia Viral Vector Vaccines Market Size by Type
9.1.1 Asia Viral Vector Vaccines Sales by Type (2018-2034)
9.1.2 Asia Viral Vector Vaccines Revenue by Type (2018-2034)
9.2 Asia Viral Vector Vaccines Market Size by Application
9.2.1 Asia Viral Vector Vaccines Sales by Application (2018-2034)
9.2.2 Asia Viral Vector Vaccines Revenue by Application (2018-2034)
9.3 Asia Viral Vector Vaccines Sales by Region
9.3.1 Asia Viral Vector Vaccines Revenue by Region: 2018 VS 2022 VS 2034
9.3.2 Asia Viral Vector Vaccines Revenue by Region (2018-2034)
9.3.3 Asia Viral Vector Vaccines Sales by Region (2018-2034)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Viral Vector Vaccines Market Size by Type
10.1.1 Middle East, Africa and Latin America Viral Vector Vaccines Sales by Type (2018-2034)
10.1.2 Middle East, Africa and Latin America Viral Vector Vaccines Revenue by Type (2018-2034)
10.2 Middle East, Africa and Latin America Viral Vector Vaccines Market Size by Application
10.2.1 Middle East, Africa and Latin America Viral Vector Vaccines Sales by Application (2018-2034)
10.2.2 Middle East, Africa and Latin America Viral Vector Vaccines Revenue by Application (2018-2034)
10.3 Middle East, Africa and Latin America Viral Vector Vaccines Sales by Country
10.3.1 Middle East, Africa and Latin America Viral Vector Vaccines Revenue by Country: 2018 VS 2022 VS 2034
10.3.2 Middle East, Africa and Latin America Viral Vector Vaccines Revenue by Country (2018-2034)
10.3.3 Middle East, Africa and Latin America Viral Vector Vaccines Sales by Country (2018-2034)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 Advanced Bioscience Laboratories
11.1.1 Advanced Bioscience Laboratories Company Information
11.1.2 Advanced Bioscience Laboratories Overview
11.1.3 Advanced Bioscience Laboratories Viral Vector Vaccines Sales, Price, Revenue and Gross Margin (2018-2024)
11.1.4 Advanced Bioscience Laboratories Viral Vector Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Advanced Bioscience Laboratories Recent Developments
11.2 Boehringer Ingelheim
11.2.1 Boehringer Ingelheim Company Information
11.2.2 Boehringer Ingelheim Overview
11.2.3 Boehringer Ingelheim Viral Vector Vaccines Sales, Price, Revenue and Gross Margin (2018-2024)
11.2.4 Boehringer Ingelheim Viral Vector Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Boehringer Ingelheim Recent Developments
11.3 Brammer Bio
11.3.1 Brammer Bio Company Information
11.3.2 Brammer Bio Overview
11.3.3 Brammer Bio Viral Vector Vaccines Sales, Price, Revenue and Gross Margin (2018-2024)
11.3.4 Brammer Bio Viral Vector Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Brammer Bio Recent Developments
11.4 Creative Biogene
11.4.1 Creative Biogene Company Information
11.4.2 Creative Biogene Overview
11.4.3 Creative Biogene Viral Vector Vaccines Sales, Price, Revenue and Gross Margin (2018-2024)
11.4.4 Creative Biogene Viral Vector Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Creative Biogene Recent Developments
11.5 GE Healthcare
11.5.1 GE Healthcare Company Information
11.5.2 GE Healthcare Overview
11.5.3 GE Healthcare Viral Vector Vaccines Sales, Price, Revenue and Gross Margin (2018-2024)
11.5.4 GE Healthcare Viral Vector Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 GE Healthcare Recent Developments
11.6 Pfizer
11.6.1 Pfizer Company Information
11.6.2 Pfizer Overview
11.6.3 Pfizer Viral Vector Vaccines Sales, Price, Revenue and Gross Margin (2018-2024)
11.6.4 Pfizer Viral Vector Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Pfizer Recent Developments
11.7 Sanofi
11.7.1 Sanofi Company Information
11.7.2 Sanofi Overview
11.7.3 Sanofi Viral Vector Vaccines Sales, Price, Revenue and Gross Margin (2018-2024)
11.7.4 Sanofi Viral Vector Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Sanofi Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Viral Vector Vaccines Industry Chain Analysis
12.2 Viral Vector Vaccines Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Viral Vector Vaccines Production Mode & Process
12.4 Viral Vector Vaccines Sales and Marketing
12.4.1 Viral Vector Vaccines Sales Channels
12.4.2 Viral Vector Vaccines Distributors
12.5 Viral Vector Vaccines Customers
13 Market Dynamics
13.1 Viral Vector Vaccines Industry Trends
13.2 Viral Vector Vaccines Market Drivers
13.3 Viral Vector Vaccines Market Challenges
13.4 Viral Vector Vaccines Market Restraints
14 Key Findings in The Global Viral Vector Vaccines Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Viral Vector Vaccines Market Size Growth Rate by Type, 2018 VS 2022 VS 2034 (US$ Million)
Table 2. Major Manufacturers of Adenovirus
Table 3. Major Manufacturers of Fowlpox Virus
Table 4. Major Manufacturers of Attenuated Yellow Fever
Table 5. Major Manufacturers of Vaccinia Virus Vectors
Table 6. Major Manufacturers of Others
Table 7. Global Viral Vector Vaccines Market Size Growth Rate by Application, 2018 VS 2022 VS 2034 (US$ Million)
Table 8. Global Viral Vector Vaccines Revenue Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 9. Global Viral Vector Vaccines Revenue by Region (2018-2024) & (US$ Million)
Table 10. Global Viral Vector Vaccines Revenue by Region (2024-2034) & (US$ Million)
Table 11. Global Viral Vector Vaccines Revenue Market Share by Region (2018-2024)
Table 12. Global Viral Vector Vaccines Revenue Market Share by Region (2024-2034)
Table 13. Global Viral Vector Vaccines Sales Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 14. Global Viral Vector Vaccines Sales by Region (2018-2024) & (K Units)
Table 15. Global Viral Vector Vaccines Sales by Region (2024-2034) & (K Units)
Table 16. Global Viral Vector Vaccines Sales Market Share by Region (2018-2024)
Table 17. Global Viral Vector Vaccines Sales Market Share by Region (2024-2034)
Table 18. Global Viral Vector Vaccines Sales by Manufacturers (2018-2024) & (K Units)
Table 19. Global Viral Vector Vaccines Sales Share by Manufacturers (2018-2024)
Table 20. Global Viral Vector Vaccines Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 21. Global Viral Vector Vaccines Revenue Share by Manufacturers (2018-2024)
Table 22. Global Key Players of Viral Vector Vaccines, Industry Ranking, 2021 VS 2022 VS 2024
Table 23. Viral Vector Vaccines Price by Manufacturers 2018-2024 (USD/Unit)
Table 24. Global Viral Vector Vaccines Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 25. Global Viral Vector Vaccines by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Viral Vector Vaccines as of 2022)
Table 26. Global Key Manufacturers of Viral Vector Vaccines, Manufacturing Base Distribution and Headquarters
Table 27. Global Key Manufacturers of Viral Vector Vaccines, Product Offered and Application
Table 28. Global Key Manufacturers of Viral Vector Vaccines, Date of Enter into This Industry
Table 29. Mergers & Acquisitions, Expansion Plans
Table 30. Global Viral Vector Vaccines Sales by Type (2018-2024) & (K Units)
Table 31. Global Viral Vector Vaccines Sales by Type (2024-2034) & (K Units)
Table 32. Global Viral Vector Vaccines Sales Share by Type (2018-2024)
Table 33. Global Viral Vector Vaccines Sales Share by Type (2024-2034)
Table 34. Global Viral Vector Vaccines Revenue by Type (2018-2024) & (US$ Million)
Table 35. Global Viral Vector Vaccines Revenue by Type (2024-2034) & (US$ Million)
Table 36. Global Viral Vector Vaccines Revenue Share by Type (2018-2024)
Table 37. Global Viral Vector Vaccines Revenue Share by Type (2024-2034)
Table 38. Viral Vector Vaccines Price by Type (2018-2024) & (USD/Unit)
Table 39. Global Viral Vector Vaccines Price Forecast by Type (2024-2034) & (USD/Unit)
Table 40. Global Viral Vector Vaccines Sales by Application (2018-2024) & (K Units)
Table 41. Global Viral Vector Vaccines Sales by Application (2024-2034) & (K Units)
Table 42. Global Viral Vector Vaccines Sales Share by Application (2018-2024)
Table 43. Global Viral Vector Vaccines Sales Share by Application (2024-2034)
Table 44. Global Viral Vector Vaccines Revenue by Application (2018-2024) & (US$ Million)
Table 45. Global Viral Vector Vaccines Revenue by Application (2024-2034) & (US$ Million)
Table 46. Global Viral Vector Vaccines Revenue Share by Application (2018-2024)
Table 47. Global Viral Vector Vaccines Revenue Share by Application (2024-2034)
Table 48. Viral Vector Vaccines Price by Application (2018-2024) & (USD/Unit)
Table 49. Global Viral Vector Vaccines Price Forecast by Application (2024-2034) & (USD/Unit)
Table 50. US & Canada Viral Vector Vaccines Sales by Type (2018-2024) & (K Units)
Table 51. US & Canada Viral Vector Vaccines Sales by Type (2024-2034) & (K Units)
Table 52. US & Canada Viral Vector Vaccines Revenue by Type (2018-2024) & (US$ Million)
Table 53. US & Canada Viral Vector Vaccines Revenue by Type (2024-2034) & (US$ Million)
Table 54. US & Canada Viral Vector Vaccines Sales by Application (2018-2024) & (K Units)
Table 55. US & Canada Viral Vector Vaccines Sales by Application (2024-2034) & (K Units)
Table 56. US & Canada Viral Vector Vaccines Revenue by Application (2018-2024) & (US$ Million)
Table 57. US & Canada Viral Vector Vaccines Revenue by Application (2024-2034) & (US$ Million)
Table 58. US & Canada Viral Vector Vaccines Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 59. US & Canada Viral Vector Vaccines Revenue by Country (2018-2024) & (US$ Million)
Table 60. US & Canada Viral Vector Vaccines Revenue by Country (2024-2034) & (US$ Million)
Table 61. US & Canada Viral Vector Vaccines Sales by Country (2018-2024) & (K Units)
Table 62. US & Canada Viral Vector Vaccines Sales by Country (2024-2034) & (K Units)
Table 63. Europe Viral Vector Vaccines Sales by Type (2018-2024) & (K Units)
Table 64. Europe Viral Vector Vaccines Sales by Type (2024-2034) & (K Units)
Table 65. Europe Viral Vector Vaccines Revenue by Type (2018-2024) & (US$ Million)
Table 66. Europe Viral Vector Vaccines Revenue by Type (2024-2034) & (US$ Million)
Table 67. Europe Viral Vector Vaccines Sales by Application (2018-2024) & (K Units)
Table 68. Europe Viral Vector Vaccines Sales by Application (2024-2034) & (K Units)
Table 69. Europe Viral Vector Vaccines Revenue by Application (2018-2024) & (US$ Million)
Table 70. Europe Viral Vector Vaccines Revenue by Application (2024-2034) & (US$ Million)
Table 71. Europe Viral Vector Vaccines Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 72. Europe Viral Vector Vaccines Revenue by Country (2018-2024) & (US$ Million)
Table 73. Europe Viral Vector Vaccines Revenue by Country (2024-2034) & (US$ Million)
Table 74. Europe Viral Vector Vaccines Sales by Country (2018-2024) & (K Units)
Table 75. Europe Viral Vector Vaccines Sales by Country (2024-2034) & (K Units)
Table 76. China Viral Vector Vaccines Sales by Type (2018-2024) & (K Units)
Table 77. China Viral Vector Vaccines Sales by Type (2024-2034) & (K Units)
Table 78. China Viral Vector Vaccines Revenue by Type (2018-2024) & (US$ Million)
Table 79. China Viral Vector Vaccines Revenue by Type (2024-2034) & (US$ Million)
Table 80. China Viral Vector Vaccines Sales by Application (2018-2024) & (K Units)
Table 81. China Viral Vector Vaccines Sales by Application (2024-2034) & (K Units)
Table 82. China Viral Vector Vaccines Revenue by Application (2018-2024) & (US$ Million)
Table 83. China Viral Vector Vaccines Revenue by Application (2024-2034) & (US$ Million)
Table 84. Asia Viral Vector Vaccines Sales by Type (2018-2024) & (K Units)
Table 85. Asia Viral Vector Vaccines Sales by Type (2024-2034) & (K Units)
Table 86. Asia Viral Vector Vaccines Revenue by Type (2018-2024) & (US$ Million)
Table 87. Asia Viral Vector Vaccines Revenue by Type (2024-2034) & (US$ Million)
Table 88. Asia Viral Vector Vaccines Sales by Application (2018-2024) & (K Units)
Table 89. Asia Viral Vector Vaccines Sales by Application (2024-2034) & (K Units)
Table 90. Asia Viral Vector Vaccines Revenue by Application (2018-2024) & (US$ Million)
Table 91. Asia Viral Vector Vaccines Revenue by Application (2024-2034) & (US$ Million)
Table 92. Asia Viral Vector Vaccines Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 93. Asia Viral Vector Vaccines Revenue by Region (2018-2024) & (US$ Million)
Table 94. Asia Viral Vector Vaccines Revenue by Region (2024-2034) & (US$ Million)
Table 95. Asia Viral Vector Vaccines Sales by Region (2018-2024) & (K Units)
Table 96. Asia Viral Vector Vaccines Sales by Region (2024-2034) & (K Units)
Table 97. Middle East, Africa and Latin America Viral Vector Vaccines Sales by Type (2018-2024) & (K Units)
Table 98. Middle East, Africa and Latin America Viral Vector Vaccines Sales by Type (2024-2034) & (K Units)
Table 99. Middle East, Africa and Latin America Viral Vector Vaccines Revenue by Type (2018-2024) & (US$ Million)
Table 100. Middle East, Africa and Latin America Viral Vector Vaccines Revenue by Type (2024-2034) & (US$ Million)
Table 101. Middle East, Africa and Latin America Viral Vector Vaccines Sales by Application (2018-2024) & (K Units)
Table 102. Middle East, Africa and Latin America Viral Vector Vaccines Sales by Application (2024-2034) & (K Units)
Table 103. Middle East, Africa and Latin America Viral Vector Vaccines Revenue by Application (2018-2024) & (US$ Million)
Table 104. Middle East, Africa and Latin America Viral Vector Vaccines Revenue by Application (2024-2034) & (US$ Million)
Table 105. Middle East, Africa and Latin America Viral Vector Vaccines Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 106. Middle East, Africa and Latin America Viral Vector Vaccines Revenue by Country (2018-2024) & (US$ Million)
Table 107. Middle East, Africa and Latin America Viral Vector Vaccines Revenue by Country (2024-2034) & (US$ Million)
Table 108. Middle East, Africa and Latin America Viral Vector Vaccines Sales by Country (2018-2024) & (K Units)
Table 109. Middle East, Africa and Latin America Viral Vector Vaccines Sales by Country (2024-2034) & (K Units)
Table 110. Advanced Bioscience Laboratories Company Information
Table 111. Advanced Bioscience Laboratories Description and Major Businesses
Table 112. Advanced Bioscience Laboratories Viral Vector Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 113. Advanced Bioscience Laboratories Viral Vector Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
Table 114. Advanced Bioscience Laboratories Recent Developments
Table 115. Boehringer Ingelheim Company Information
Table 116. Boehringer Ingelheim Description and Major Businesses
Table 117. Boehringer Ingelheim Viral Vector Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 118. Boehringer Ingelheim Viral Vector Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
Table 119. Boehringer Ingelheim Recent Developments
Table 120. Brammer Bio Company Information
Table 121. Brammer Bio Description and Major Businesses
Table 122. Brammer Bio Viral Vector Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 123. Brammer Bio Viral Vector Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
Table 124. Brammer Bio Recent Developments
Table 125. Creative Biogene Company Information
Table 126. Creative Biogene Description and Major Businesses
Table 127. Creative Biogene Viral Vector Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 128. Creative Biogene Viral Vector Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
Table 129. Creative Biogene Recent Developments
Table 130. GE Healthcare Company Information
Table 131. GE Healthcare Description and Major Businesses
Table 132. GE Healthcare Viral Vector Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 133. GE Healthcare Viral Vector Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
Table 134. GE Healthcare Recent Developments
Table 135. Pfizer Company Information
Table 136. Pfizer Description and Major Businesses
Table 137. Pfizer Viral Vector Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 138. Pfizer Viral Vector Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
Table 139. Pfizer Recent Developments
Table 140. Sanofi Company Information
Table 141. Sanofi Description and Major Businesses
Table 142. Sanofi Viral Vector Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 143. Sanofi Viral Vector Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
Table 144. Sanofi Recent Developments
Table 145. Key Raw Materials Lists
Table 146. Raw Materials Key Suppliers Lists
Table 147. Viral Vector Vaccines Distributors List
Table 148. Viral Vector Vaccines Customers List
Table 149. Viral Vector Vaccines Market Trends
Table 150. Viral Vector Vaccines Market Drivers
Table 151. Viral Vector Vaccines Market Challenges
Table 152. Viral Vector Vaccines Market Restraints
Table 153. Research Programs/Design for This Report
Table 154. Key Data Information from Secondary Sources
Table 155. Key Data Information from Primary Sources
List of Figures
Figure 1. Viral Vector Vaccines Product Picture
Figure 2. Global Viral Vector Vaccines Market Size Growth Rate by Type, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Viral Vector Vaccines Market Share by Type in 2022 & 2034
Figure 4. Adenovirus Product Picture
Figure 5. Fowlpox Virus Product Picture
Figure 6. Attenuated Yellow Fever Product Picture
Figure 7. Vaccinia Virus Vectors Product Picture
Figure 8. Others Product Picture
Figure 9. Global Viral Vector Vaccines Market Size Growth Rate by Application, 2018 VS 2022 VS 2034 (US$ Million)
Figure 10. Global Viral Vector Vaccines Market Share by Application in 2022 & 2034
Figure 11. Hospitals
Figure 12. Clinics
Figure 13. Others
Figure 14. Viral Vector Vaccines Report Years Considered
Figure 15. Global Viral Vector Vaccines Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 16. Global Viral Vector Vaccines Revenue 2018-2034 (US$ Million)
Figure 17. Global Viral Vector Vaccines Revenue Market Share by Region in Percentage: 2022 Versus 2034
Figure 18. Global Viral Vector Vaccines Revenue Market Share by Region (2018-2034)
Figure 19. Global Viral Vector Vaccines Sales 2018-2034 ((K Units)
Figure 20. Global Viral Vector Vaccines Sales Market Share by Region (2018-2034)
Figure 21. US & Canada Viral Vector Vaccines Sales YoY (2018-2034) & (K Units)
Figure 22. US & Canada Viral Vector Vaccines Revenue YoY (2018-2034) & (US$ Million)
Figure 23. Europe Viral Vector Vaccines Sales YoY (2018-2034) & (K Units)
Figure 24. Europe Viral Vector Vaccines Revenue YoY (2018-2034) & (US$ Million)
Figure 25. China Viral Vector Vaccines Sales YoY (2018-2034) & (K Units)
Figure 26. China Viral Vector Vaccines Revenue YoY (2018-2034) & (US$ Million)
Figure 27. Asia (excluding China) Viral Vector Vaccines Sales YoY (2018-2034) & (K Units)
Figure 28. Asia (excluding China) Viral Vector Vaccines Revenue YoY (2018-2034) & (US$ Million)
Figure 29. Middle East, Africa and Latin America Viral Vector Vaccines Sales YoY (2018-2034) & (K Units)
Figure 30. Middle East, Africa and Latin America Viral Vector Vaccines Revenue YoY (2018-2034) & (US$ Million)
Figure 31. The Viral Vector Vaccines Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2022
Figure 32. The Top 5 and 10 Largest Manufacturers of Viral Vector Vaccines in the World: Market Share by Viral Vector Vaccines Revenue in 2022
Figure 33. Global Viral Vector Vaccines Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 34. Global Viral Vector Vaccines Sales Market Share by Type (2018-2034)
Figure 35. Global Viral Vector Vaccines Revenue Market Share by Type (2018-2034)
Figure 36. Global Viral Vector Vaccines Sales Market Share by Application (2018-2034)
Figure 37. Global Viral Vector Vaccines Revenue Market Share by Application (2018-2034)
Figure 38. US & Canada Viral Vector Vaccines Sales Market Share by Type (2018-2034)
Figure 39. US & Canada Viral Vector Vaccines Revenue Market Share by Type (2018-2034)
Figure 40. US & Canada Viral Vector Vaccines Sales Market Share by Application (2018-2034)
Figure 41. US & Canada Viral Vector Vaccines Revenue Market Share by Application (2018-2034)
Figure 42. US & Canada Viral Vector Vaccines Revenue Share by Country (2018-2034)
Figure 43. US & Canada Viral Vector Vaccines Sales Share by Country (2018-2034)
Figure 44. U.S. Viral Vector Vaccines Revenue (2018-2034) & (US$ Million)
Figure 45. Canada Viral Vector Vaccines Revenue (2018-2034) & (US$ Million)
Figure 46. Europe Viral Vector Vaccines Sales Market Share by Type (2018-2034)
Figure 47. Europe Viral Vector Vaccines Revenue Market Share by Type (2018-2034)
Figure 48. Europe Viral Vector Vaccines Sales Market Share by Application (2018-2034)
Figure 49. Europe Viral Vector Vaccines Revenue Market Share by Application (2018-2034)
Figure 50. Europe Viral Vector Vaccines Revenue Share by Country (2018-2034)
Figure 51. Europe Viral Vector Vaccines Sales Share by Country (2018-2034)
Figure 52. Germany Viral Vector Vaccines Revenue (2018-2034) & (US$ Million)
Figure 53. France Viral Vector Vaccines Revenue (2018-2034) & (US$ Million)
Figure 54. U.K. Viral Vector Vaccines Revenue (2018-2034) & (US$ Million)
Figure 55. Italy Viral Vector Vaccines Revenue (2018-2034) & (US$ Million)
Figure 56. Russia Viral Vector Vaccines Revenue (2018-2034) & (US$ Million)
Figure 57. China Viral Vector Vaccines Sales Market Share by Type (2018-2034)
Figure 58. China Viral Vector Vaccines Revenue Market Share by Type (2018-2034)
Figure 59. China Viral Vector Vaccines Sales Market Share by Application (2018-2034)
Figure 60. China Viral Vector Vaccines Revenue Market Share by Application (2018-2034)
Figure 61. Asia Viral Vector Vaccines Sales Market Share by Type (2018-2034)
Figure 62. Asia Viral Vector Vaccines Revenue Market Share by Type (2018-2034)
Figure 63. Asia Viral Vector Vaccines Sales Market Share by Application (2018-2034)
Figure 64. Asia Viral Vector Vaccines Revenue Market Share by Application (2018-2034)
Figure 65. Asia Viral Vector Vaccines Revenue Share by Region (2018-2034)
Figure 66. Asia Viral Vector Vaccines Sales Share by Region (2018-2034)
Figure 67. Japan Viral Vector Vaccines Revenue (2018-2034) & (US$ Million)
Figure 68. South Korea Viral Vector Vaccines Revenue (2018-2034) & (US$ Million)
Figure 69. China Taiwan Viral Vector Vaccines Revenue (2018-2034) & (US$ Million)
Figure 70. Southeast Asia Viral Vector Vaccines Revenue (2018-2034) & (US$ Million)
Figure 71. India Viral Vector Vaccines Revenue (2018-2034) & (US$ Million)
Figure 72. Middle East, Africa and Latin America Viral Vector Vaccines Sales Market Share by Type (2018-2034)
Figure 73. Middle East, Africa and Latin America Viral Vector Vaccines Revenue Market Share by Type (2018-2034)
Figure 74. Middle East, Africa and Latin America Viral Vector Vaccines Sales Market Share by Application (2018-2034)
Figure 75. Middle East, Africa and Latin America Viral Vector Vaccines Revenue Market Share by Application (2018-2034)
Figure 76. Middle East, Africa and Latin America Viral Vector Vaccines Revenue Share by Country (2018-2034)
Figure 77. Middle East, Africa and Latin America Viral Vector Vaccines Sales Share by Country (2018-2034)
Figure 78. Brazil Viral Vector Vaccines Revenue (2018-2034) & (US$ Million)
Figure 79. Mexico Viral Vector Vaccines Revenue (2018-2034) & (US$ Million)
Figure 80. Turkey Viral Vector Vaccines Revenue (2018-2034) & (US$ Million)
Figure 81. Israel Viral Vector Vaccines Revenue (2018-2034) & (US$ Million)
Figure 82. GCC Countries Viral Vector Vaccines Revenue (2018-2034) & (US$ Million)
Figure 83. Viral Vector Vaccines Value Chain
Figure 84. Viral Vector Vaccines Production Process
Figure 85. Channels of Distribution
Figure 86. Distributors Profiles
Figure 87. Bottom-up and Top-down Approaches for This Report
Figure 88. Data Triangulation
Figure 89. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries